Convalescent plasma did not prevent disease progression in a high risk group of outpatients with COVID-19 when administered within the first week of their symptoms, according to the final results of the clinical trial funded by US medical agency.
The study funded by the National heart, lung, and blood institute, part of the national institutes of health, and by the biomedical advanced research and development authority, part of the office of the assistant secretary for preparedness and response at the US department of health and human services, was published in an online issue of the new England journal of Medicine. The convalescent plasma in outpatient trial was stopped in February due to lack of efficacy based on a planned interim analysis, according to the official statement. We were hoping that the use of COVID 19 convalescent plasma would achieve at least a 10% reduction in disease progression in this group, but instead the reduction we observed was less than 2%. Additional studies of COVID 19 convalescent plasma are ongoing or planned in various populations.